Posts

Posted on

Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

— Company now expects to complete enrollment of 150 patients in Q2 2026, with a Phase 3 data readout in mid-2027; Rolling NDA submission planned to initiate in first half 2027—

— Discussions with FDA ongoing following recent multidisciplinary meeting; Company continues to explore potential for expedited development, registration and delivery of zorevunersen to patients —

—Company to present at 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 —

BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development with Biogen (Nasdaq: BIIB) as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced accelerated timelines for the completion of enrollment and a Phase 3 data readout from the EMPEROR study. Completion of enrollment of 150 patients is now expected in the second quarter of 2026. This enrollment progress puts the Phase 3 EMPEROR study on track for a data readout in mid-2027 that is anticipated to support the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). The Company plans to initiate a rolling NDA submission in the first half of 2027.

In addition, as part of zorevunersen’s Breakthrough Therapy Designation, a multidisciplinary meeting was held with the FDA to discuss the ongoing clinical development of zorevunersen, including the exploration of potential expedited regulatory pathways. No immediate changes to the zorevunersen development program were agreed to at the meeting. The FDA has requested additional information, and discussions between the Company and the Agency are ongoing regarding potential opportunities to expeditethe development, registration and delivery of zorevunersen to patients.

“The rate of enrollment in the Phase 3 EMPEROR study is highly encouraging and supports the significant need for a disease-modifying treatment for Dravet syndrome. The accelerated timing for completion of enrollment of 150 patients, in addition to Breakthrough Therapy Designation, positions us to initiate a rolling NDA submission in the first half of 2027 resulting in the potential to deliver zorevunersen to patients sooner than originally expected,” said Ian F. Smith, Chief Executive Officer and Director of Stoke Therapeutics. “Our recent multidisciplinary meeting was productive and we appreciate the FDA’s interest in deepening their understanding of Dravet syndrome and its impacts on patients and their families while also taking time to review and discuss our four years of clinical data. Subsequently, we have responded to the Agency’s request for additional information and we look forward to continuing to engage with them as part of our commitment to explore every opportunity to deliver zorevunersen to patients as quickly as possible.”

As of January 9, 2026, nearly 330 patients globally had been identified by investigators as potential study candidates. Of these, approximately 60 patients are currently in the formal 8-week screening period that immediately precedes randomization and an additional approximately 60 patients have advanced to randomization and dosing.

Financial Guidance

The Company has approximately $391.7 million in cash, cash equivalents and marketable securities as of December 31, 2025. These funds, combined with eligible proceeds from the Biogen collaboration, are anticipated to fund operations into 2028.

J.P. Morgan Healthcare Conference Webcast Information

Chief Executive Officer Ian F. Smith will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 7:30 p.m. Eastern Time (4:30 p.m. Pacific Time) in San Francisco, CA. A live audio webcast of the presentation will be available on the Investors & News section of Stoke’s website at https://investor.stoketherapeutics.com/ and can be accessed by following this Link. A replay of the webcast will be available for 30 days following the presentation.

About Dravet Syndrome

Dravet syndrome is a severe developmental and epileptic encephalopathy (DEE) characterized by recurrent seizures as well as significant cognitive and behavioral impairments. Most cases of Dravet are caused by mutations in one copy of the SCN1A gene, leading to insufficient levels of NaV1.1 protein in neuronal cells in the brain. Even when treated with the best available anti-seizure medicines (ASMs), up to 57 percent of patients with Dravet syndrome do not achieve ≥50 percent reduction in seizure frequency. Complications of the disease often contribute to a poor quality of life for patients and their caregivers. Developmental and cognitive impairments often include intellectual disability, developmental delays, movement and balance issues, language and speech disturbances, growth defects, sleep abnormalities, disruptions of the autonomic nervous system and mood disorders. Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP; up to 20 percent of children and adolescents with Dravet syndrome die before adulthood due to SUDEP, prolonged seizures, seizure-related accidents or infections1. Dravet syndrome occurs globally and is not concentrated in a particular geographic area or ethnic group. Currently, it is estimated that up to 38,000 people are living with Dravet syndrome in the U.S. (~16,000), UK, EU-4 and Japan.2 There are no approved disease-modifying therapies for people living with Dravet syndrome.

About Zorevunersen

Zorevunersen is an investigational antisense oligonucleotide that is designed to treat the underlying cause of Dravet syndrome by increasing functional NaV1.1 protein production in brain cells from the non-mutated (wild-type) copy of the SCN1A gene. This highly differentiated mechanism of action aims to reduce seizure frequency beyond what has been achieved with anti-seizure medicines and to improve neurodevelopment, cognition and behavior. Zorevunersen has demonstrated the potential for disease modification and has been granted orphan drug designation by the FDA and the EMA. The FDA has also granted zorevunersen rare pediatric disease designation and Breakthrough Therapy Designation for the treatment of Dravet syndrome with a confirmed mutation not associated with gain-of-function, in the SCN1A gene. Stoke has a strategic collaboration with Biogen to develop and commercialize zorevunersen for Dravet syndrome. Under the collaboration, Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights.

About the EMPEROR Study

The EMPEROR Phase 3 Study (NCT06872125) is a global, double-blind, sham-controlled study evaluating the efficacy, safety and tolerability of zorevunersen in children ages 2 to <18 with Dravet syndrome with a confirmed variant in the SCN1A gene not associated with gain-of-function. The trial is currently enrolling approximately 150 patients in the United States, United Kingdom and Japan which are anticipated to support an NDA. At least 20 additional patients are expected to enroll in Germany, Spain, France and Italy starting in the second quarter of 2026. Participants are randomized 1:1 to receive either zorevunersen via intrathecal administration or a sham comparator for a 52-week treatment period following an 8-week baseline period. Following the completion of the study treatment period, eligible participants will be offered ongoing treatment with zorevunersen as part of an OLE study. The primary endpoint of the study is percent change from baseline in major motor seizure frequency at week 28 in patients receiving zorevunersen as compared to sham. The key secondary endpoints are the durability of effect on major motor seizure frequency and improvements in behavior and cognition as measured by Vineland-3 subdomains, including expressive communication, receptive communication, interpersonal relationships, coping skills and personal skills. Additional endpoints include safety, Clinician Global Impression of Change (CGI-C), Caregiver Global Impression of Change (CaGI-C) and the Bayley Scales of Infant Development (BSID-IV). For more information, visit https://www.emperorstudy.com/.

About Stoke Therapeutics

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/.

Stoke Therapeutics Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the ability of zorevunersen to treat the underlying causes of Dravet syndrome and reduce seizures or show improvements in behavior and cognition at the indicated dosing levels or at all; the potential benefits, safety and efficacy of zorevunersen; the timing and expected progress of clinical trials, data readouts, regulatory meetings, regulatory decisions and other presentations; the characterization of the Company’s meeting and discussions with the FDA; and the ability of the Company to achieve an NDA submission or approval on the expedited timeframe disclosed or at all. Statements including words such as “plan,” “potential,” “will,” “continue,” “expect,” or similar words and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they prove incorrect or do not fully materialize, could cause Stoke’s results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to: the Company’s ability to advance, obtain regulatory approval and ultimately commercialize its product candidates; that if collaborators were to breach or terminate their agreements, the Company would not obtain the anticipated financial or other benefits; the possibility that the Company and Biogen may not be successful in their development of zorevunersen and that, even if successful, they may be unable to successfully commercialize zorevunersen; positive results in a clinical trial may not be replicated in subsequent trials or successes in early stage clinical trials may not be predictive of results in later stage trials; the Company’s ability to protect its intellectual property; the Company’s ability to fund development activities and achieve development goals into 2028; and the other risks and uncertainties described under the heading “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2024, its quarterly reports on Form 10-Q, and the other documents it files with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

References:

  1. Symonds, J. et al. Early childhood epilepsies: epidemiology, classification, aetiology, and socio-economic determinants. Brain. 2021;144(9):2879-2891.

  2. Based on Stoke Therapeutics’ preliminary estimates, which scaled annual incidence to prevalence using country-specific live birth rates over the past 85 years and adjusted for Dravet-specific mortality. The estimate is based on incidence rates published by Wu et al., Pediatrics, 2015.

 

Media & Investor Contacts:

Susan Willson

Vice President, Corporate Communications

[email protected]

415-509-8202

Doug Snow

Director, Communications & Investor Relations

[email protected]

508-642-6485

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Health Genetics Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA:

Logo
Logo
Posted on

SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit

PR Newswire

NEW YORK, Jan. 11, 2026 /PRNewswire/ —

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the “Class Period”), of the important January 16, 2026 lead plaintiff deadline.

So what: If you purchased Skye securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Skye Bioscience, Inc. class action, go to https://rosenlegal.com/submit-form/?case_id=48064  or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 16, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements regarding Skye’s business, operations, and prospects. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (1) nimacimab was less effective than defendants had led investors to believe; (2) accordingly, nimacimab’s clinical, regulatory, and commercial prospects were overstated; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Skye Bioscience class action, go to https://rosenlegal.com/submit-form/?case_id=48064 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/skye-deadline-skye-investors-have-opportunity-to-lead-skye-bioscience-inc-securities-fraud-lawsuit-302657710.html

SOURCE THE ROSEN LAW FIRM, P. A.

Posted on

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million

Robust clinical pipeline with multibillion dollar opportunities and strong balance sheet for sustained growth

PITTSBURGH, Jan. 11, 2026 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced selected preliminary unaudited 2025 financial results, including fourth quarter and full year 2025 VYJUVEK® net product revenue, and outlined the Company’s strategic vision to drive the next stage of growth of its rare disease business. These topics will be discussed during the Company’s presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco tomorrow, Monday, January 12, 2026, at 10:30 am ET / 7:30 am PT.

“2025 was a standout year for Krystal, with the successful launch of VYJUVEK in Europe and Japan setting the foundation for our broader ambitions to build a true global leader in rare disease,” said Krish S. Krishnan, Chairman and CEO of Krystal Biotech. “As we execute on the next stage of our growth story, we will be leaning into our strengths – the strengths of our HSV-1 platform and the strengths of our organization – and focusing in on rare disease indications where we can move quickly and launch truly differentiated and impactful redosable genetic medicines. With multiple potential blockbuster launches in the next four years, as well as a strong growth outlook for VYJUVEK, we are well positioned to execute on this vision and deliver transformational outcomes for patients.”

Preliminary and Unaudited Fourth Quarter and Full Year 2025 Financial Updates

Based on preliminary unaudited financial information, the Company expects net product revenue for VYJUVEK to be between $106 million and $107 million for the fourth quarter of 2025. VYJUVEK net revenue for the full year 2025 is expected to be between $388 million and $389 million.

Cash, cash equivalents, and investments were approximately $955 million as of December 31, 2025.

These preliminary unaudited results are based on management’s initial analysis of operations for the year ended December 31, 2025 and subject to adjustment. The Company will report its full financial results for the fourth quarter and full year 2025 in February 2026.

Rare Disease Strategic Vision and 2026 Corporate Objectives

Over 300 million people around the world are living with rare diseases, many of whom lack adequate therapies. With global rare disease drug development and launch infrastructure and a redosable HSV-1 platform with Platform Technology Designation that is well-suited for gene delivery to high turnover tissues in the skin, lung, and eye, the Company is uniquely positioned to help fill this treatment gap.

To that end, the Company is accelerating and expanding clinical development efforts for its rare disease pipeline of programs:

  • KB803 for ocular complications of dystrophic epidermolysis bullosa (DEB)
  • KB801 for neurotrophic keratitis (NK)
  • KB407 for cystic fibrosis (CF)
  • KB111 for Hailey-Hailey disease (HHD)

In support of potential expedited development of KB801 for the treatment of NK, the Company has increased the enrollment target of its ongoing registrational double-masked, randomized, placebo-controlled study from 27 to 60 patients. The Company will provide a detailed update on the registrational study design when it reports its 2025 financial results in February 2026. Top line data from the study is expected before the end of 2026.

The Company’s strategic vision is to have at least four marketed rare disease medicines, inclusive of VYJUVEK, by the end of 2030, treating over 10,000 patients worldwide.

The Company expects to achieve these goals while remaining profitable throughout the period and continuing to invest strategically across its broader preclinical and clinical pipeline, including programs targeting larger indications such as KB408 for alpha-1 antitrypsin deficiency and KB707 for non-small cell lung cancer.

To achieve the Company’s broader ambitions in rare disease, the Company’s corporate objectives for 2026 include:

  • Launch VYJUVEK in at least one more major European market and expand specialty distributor network to cover over 40 countries
  • Report top-line results from its registrational Phase 3 study evaluating KB803 for the treatment of ocular complications of DEB
  • Report top-line results from its registrational double-masked, randomized, placebo-controlled study evaluating KB801 for the treatment of NK
  • Initiate and complete enrollment in a registrational repeat dose study evaluating KB407 for the treatment of CF
  • Dose first patient in registrational double-blind, intra-patient randomized, placebo-controlled study evaluating KB111 in HHD patients

The Company also expects to report updates for both KB408 and KB707 before the end of the year.

Non-GAAP Research & Development (R&D) and Selling, General & Administrative (SG&A) Expense Guidance for 2026

Based on its current operating plans, the Company expects its combined non-GAAP R&D and SG&A expense in 2026 to be between $175 million and $195 million. Non-GAAP R&D and SG&A expense does not include stock-based compensation.

44

th

Annual J.P. Morgan Healthcare Conference Presentation and Webcast

Krish S. Krishnan, Chairman and Chief Executive Officer, and Suma M. Krishnan, President of Research and Development, will highlight these updates and Krystal’s strategic vision in a presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 10:30 am ET / 7:30 am PT.

A webcast of the presentation will be available here beginning at 10:30 am ET / 7:30 am PT on Monday, January 12, 2026 and will be posted on the Investors section of the Company’s website.

About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).

Forward-Looking Statements

Statements in this press release about future expectations, plans, and prospects, as well as statements that are not historical facts, including statements about, among other topics, our selected preliminary and unaudited financial results for 2025; our strategic vision and our 2026 corporate goals; our combined R&D and SG&A expense guidance; and our expectations for our product pipeline, including clinical trial plans, enrollment in clinical trials, and the timing of initiating clinical trials, dosing patients, data read-outs, and regulatory submissions may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Undue reliance should not be placed on the forward-looking statements in this press release. These statements are not guaranties of future performance and actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; the availability or commercial potential of VYJUVEK or our product candidates; and such other important factors as are set forth under the caption “Risk Factors” in the Company’s annual and quarterly reports on file with the U.S. Securities and Exchange Commission. The Company is providing the information in this press release as of the date hereof and undertakes no duty to update this information unless required by law.

Non-GAAP Financial Measure

This press release includes forward-looking combined R&D and SG&A expense guidance that is not required by, or presented in accordance with, U.S. GAAP. The Company believes this non-GAAP financial measure is useful to investors as a supplemental measure to evaluate operating performance. The Company has not provided a quantitative reconciliation of forecasted non-GAAP combined R&D and SG&A expense to forecasted GAAP combined R&D and SG&A expense because the Company is unable, without making unreasonable efforts, to calculate the reconciling item, stock-based compensation expenses, with confidence. This item, which could materially affect the computation of forward-looking GAAP combined R&D and SG&A expense, is inherently uncertain and depends on various factors, some of which are outside of the Company’s control.

CONTACT

Investors and Media:

Stéphane Paquette
Krystal Biotech
[email protected]



Posted on

Commerce Supports Universal Commerce Protocol, Plans to Offer Buying Directly Across Google’s AI Surfaces

New standard creates a common language for agents and systems across the entire shopping journey from discovery and buying to post-purchase experiences

AUSTIN, Texas, Jan. 11, 2026 (GLOBE NEWSWIRE) — Commerce (Nasdaq: CMRC), an open, intelligent ecosystem of technology solutions and the parent company of leading ecommerce platform BigCommerce and data feed optimization leader Feedonomics, today announced its endorsement of Google’s new Universal Commerce Protocol (UCP).

The new, open-source standard creates a common language for agents and systems to work together across the entire shopping journey from discovery and buying to post-purchase experiences. So instead of building a new connection for every agent, they can all interact seamlessly providing merchants with a frictionless way to reach customers across the entire AI ecosystem.

“AI is rapidly reshaping commerce. Merchants need to make it easy for shoppers to go from discovery to purchase, or they risk losing sales,” said Sharon Gee, senior vice president of product for AI at Commerce. “At the same time, keeping product data structured and enriched for AI can be resource-intensive. Our ongoing work with Google ensures merchants are not only present but competitive in AI-driven environments where consumers are searching and shopping.”

To start, UCP will soon enable a new checkout feature on product listings in AI Mode in Search and the Gemini app, allowing shoppers to buy directly from eligible US retailers and Commerce merchants right as they’re researching on Google.

“For agentic commerce to scale, it’s critical for the industry to align on a common set of standards,” said Ashish Gupta, vice president and general manager of merchant shopping at Google. “We are proud to have Commerce endorse the Universal Commerce Protocol as the foundation for that future.”

Discovery is shifting from traditional search that returns results to a specific query to conversational answer engines with embedded buying opportunities. Agent-driven shopping generates more specific, higher intent queries with consumers who know what they want and are ready to purchase it. Merchants must be strategic about how they show up in answer engines and remove barriers that prevent shoppers from making a purchase.

As part of the collaboration, Commerce is building toward the protocol to allow merchants to:

  • Enable buying directly within Google’s AI experiences, helping to secure transactions at the moment of intent
  • Remain merchant of record, retaining full ownership of the customer relationship and transaction data
  • Future-proof their business with a unified open standard to power additional commerce actions

The UCP endorsement builds on the ongoing Google and Commerce partnership, utilizing Commerce’s key differentiator: its Feedonomics-powered data enrichment layer. This layer structures and optimizes product feeds to align with Google’s schema, dynamically enhancing titles, attributes, and taxonomy to ensure high-quality data that boosts product visibility, improves match rates, and conversion with the Google ecosystem.

Learn more about Google’s new UCP here: https://blog.google/products/ads-commerce/agentic-commerce-ai-tools-protocol-retailers-platforms/

Learn more about how Commerce is powering the era of agentic commerce here: https://www.commerce.com/agentic-commerce/

About Commerce


Commerce
 (Nasdaq: CMRC) empowers businesses to innovate, grow, and thrive by providing an open, AI-driven commerce ecosystem. As the parent company of BigCommerce, Feedonomics, and Makeswift, Commerce connects the tools and systems that power growth, enabling businesses to unlock the full potential of their data, deliver seamless and personalized experiences across every channel, and adapt swiftly to an ever-changing market. Trusted by leading businesses like Coldwater Creek, Cole Haan, Harvey Nichols, King Arthur Baking Co., Mizuno, Perry Ellis, SportsShoes and Uplift Desk, Commerce delivers the storefront control, optimized data, and AI-ready tools businesses need to grow, serve diverse buyers, and operate with confidence in an increasingly intelligent, multi-surface world. For more information, visit commerce.com or follow us on X and LinkedIn.

BigCommerce®, the Commerce logo, and other brands are the trademarks or registered trademarks of BigCommerce Pty. Ltd. Third-party trademarks and service marks are the property of their respective owner.

Media Contact:

Brad Hem
[email protected]



Posted on

Honeywell Unveils AI-Enabled Technology to Personalize In-store Shopping with Google Cloud

PR Newswire

New Smart Shopping Platform, developed in collaboration with 66degrees, brings digitally enhanced personalization and navigation to the brick-and-mortar retail environment with Google’s AI.

NEW YORK, Jan. 11, 2026 /PRNewswire/ — Honeywell (Nasdaq: HON) today announced the launch of an AI-enabled retail solution developed in collaboration with Google Cloud and 66degrees that leverages Google’s Gemini and Google Cloud’s Vertex AI platform to transform the in-store shopping experience for retailers worldwide. The Smart Shopping Platform helps shoppers easily locate desired products, compare similar items and quickly find relevant substitutions when products are unavailable, making in-store shopping more efficient and enjoyable.

“There is nothing more frustrating than roaming through a store unable to find the last item on your grocery list or forgetting the key part needed to complete a home repair,” said David Barker, president, Honeywell Productivity Solutions and Services. ”The Smart Shopping Platform addresses these pain points, creating a better experience for shoppers. Retailers also benefit from an ’out of the box’ AI solution they can implement without having to maintain a team of AI experts.”

The Smart Shopping Platform is a cloud-based solution that creates a seamless connection between a retailer’s digital data and the physical store environment. Built on Honeywell’s Mobility Edge™ hardware and software platform and enabled by Google Cloud’s AI technologies, it offers personalized guidance, real-time product information and dynamic recommendations that mirror the convenience of online shopping.

“The Smart Shopping Platform uses Google Cloud’s AI to turn Honeywell devices into intelligent companions for both shoppers and staff,” said Jose Gomes, vice president, Retail and Consumer Packaged Goods, Google Cloud. “This collaboration integrates AI with specialized hardware to streamline operations inside the retail store and guide consumers through an efficient and delightful shopping journey. It’s a win-win that helps retailers increase basket size while building deeper customer loyalty.”

When using the platform on a Honeywell for Android device—such as the CS32 Personal Shopper—consumers can link their loyalty accounts to immediately unlock personalized recommendations based on buying history, stated preferences, complementary products and available discounts and promotions. The Smart Shopping Platform can also provide step-by-step navigation through the store to help customers easily locate everything they wish to buy. If a specific product is out of stock, the system uses AI to suggest relevant alternatives, mirroring the convenience of e-commerce.

The solution also supports retail workers by helping them become in-house experts. Associates equipped with devices like the Honeywell CT70 can use the Smart Shopping Platform to provide quick, customized guidance and insights to shoppers, helping every employee serve as a subject matter expert. For example, an employee can quickly identify the new location of a customer’s favorite dairy-free cereal in the store. Today, devices like the Honeywell CT70 are used by thousands of retail associates at major grocery chains, big box stores, specialty retailers, department stores and more.

This launch is the result of the ongoing collaboration between Honeywell and Google Cloud to help advance computing across multiple industries. The Smart Shopping Platform will be available to customers beginning in February 2026.

To learn more about Honeywell’s innovative solutions across the retail landscape, visit: https://automation.honeywell.com/us/en/solutions/productivity.

About Honeywell 

Honeywell is an integrated operating company serving a broad range of industries and geographies around the world, with a portfolio that is underpinned by our Honeywell Accelerator operating system and Honeywell Forge platform. As a trusted partner, we help organizations solve the world’s toughest, most complex challenges, providing actionable solutions and innovations for aerospace, building automation, industrial automation, process automation, and process technology, that help make the world smarter and safer as well as more secure and sustainable. For more news and information on Honeywell, please visit www.honeywell.com/newsroom.

About Honeywell Productivity Solutions and Services

Productivity Solutions and Services creates mobile computers, scanners, software and other data capture devices to improve worker productivity across key industries like retail, transportation, logistics and healthcare. An innovator in Automatic Identification and Data Collection (AIDC) and a leader in industrial products since the 1970s, the business is shaping the future by finding novel ways to significantly improve the efficiency, speed and accuracy of our customers’ complex operations.

About Google Cloud

Google Cloud is the new way to the cloud, providing AI, infrastructure, developer, data, security, and collaboration tools built for today and tomorrow. Google Cloud offers a powerful, fully integrated, and optimized AI stack with its own planet-scale infrastructure, custom-built chips, generative AI models, and development platform, as well as AI-powered applications, to help organizations transform. Customers in more than 200 countries and territories turn to Google Cloud as their trusted technology partner.

About 66degrees

66degrees is a Google Cloud Partner Advantage Premier level partner empowering organizations to thrive in the age of AI. The company delivers expertise in platform modernization, data transformation, and AI/ML implementation with a proven enterprise track record. With a global footprint of experts, 66degrees helps clients by focusing on three key pillars: modernizing data and infrastructure for AI, building AI platforms and applications, and managing and scaling those AI platforms.

Media Contact: 
Carly Ingersoll 
+1 (704) 626-1374 
[email protected] 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/honeywell-unveils-ai-enabled-technology-to-personalize-in-store-shopping-with-google-cloud-302657684.html

SOURCE Honeywell

Posted on

Kroger Scales Generative AI Strategy with Google Cloud to Drive Digital Growth and Personalization

PR Newswire

Kroger will use Google Cloud new agentic platform, Gemini Enterprise for Customer Experience, to simplify and transform how customers shop and eat

CINCINNATI and SUNNYVALE, Calif., Jan. 11, 2026 /PRNewswire/ — The Kroger Co. (NYSE: KR) today announced an expanded relationship with Google Cloud. The leading grocery chain will use the Gemini Enterprise for Customer Experience (CX) solution to support its customer experience transformation, combining cutting-edge technology with the care, food knowledge and understanding customers expect from Kroger – all into a new personal shopping assistant.

Under the expansion Kroger will roll out Gemini Enterprise for CX nationwide to help make grocery planning easier through an integrated Meal assistant and Shopping assistant –providing faster shopping, without compromising on unique customer preferences. 

In addition to deploying Gemini Enterprise for CX, Kroger will also use Customer Experience Agent Studio to analyze interactions and intent on calls made by customers to stores to proactively identify and resolve issues earlier, enhance associate productivity, and deliver a more seamless, “white-glove” experience nationwide.

“We know our customers want an experience that is seamless and adapts to the context of their day, and the Shopping assistant is one more way we will transform how our customers will engage with us,” said Yael Cosset, executive vice president and chief digital officer for Kroger. “A customer planning a week of dinners, seeking recipe inspiration, or jumping into a new food regimen, will be able to ask our integrated assistant to create a shopping list based on their immediate needs, their budget, and family’s unique preferences. We are streamlining every aspect of the shopping experience from building a basket and getting relevant offers and savings, to scheduling a delivery faster than ever before. We are making grocery shopping simpler and more personal, creating more time for real connections around foods families love.”

Building a Personal Shopping Companion

Kroger has been helping families find foods they love for nearly 150 years, by removing the need for customers to compromise on the choice of product, including innovative Our Brands products, offering more options to shop how they want in store, through pickup or delivery, and providing personalized offers and value to each customer.

Kroger’s Shopping assistant will build upon this foundation, reducing the time it takes to complete complex, multi-step tasks without requiring a lot of input from customers. The Shopping assistant incorporates AI-enabled features such as:

  • Intelligent execution: Agentic integration, allowing the assistant to complete complex tasks from a single instruction—such as explore meal ideas, build complex carts for a big occasion, reorder a past purchase, or compare product details.
  • Inspiration-to-cart flow: Converts a customer request, like “I want to prepare vegan tomato soup” into a guided recipe, with a detailed ingredient list, that can be added to their shopping carts with a single click.
  • Accurate and grounded: Makes recommendations based on Kroger’s proprietary data asset and grounded in actual assortment, pricing, and availability, meaning customers receive relevant, reliable suggestions they can act on immediately. The Shopping assistant takes advantage of Kroger’s precise understanding of customer needs, and will deliver a complete solution—from finding value, to planning, to purchasing a full meal—that every member of the family will enjoy.

“Kroger is pioneering the future of commerce by embracing true generative and agentic AI at the heart of their customer journey,” said Darshan Kantak, vice president of product for applied AI at Google Cloud. “With Gemini Enterprise for Commerce, Kroger will be setting a new standard for grocery, ensuring its agent becomes a comprehensive digital concierge across every customer touchpoint.”

About The Kroger Co.

At The Kroger Co. (NYSE: KR), we are dedicated to our Purpose: To Feed the Human Spirit™. We are, across our family of companies more than 400,000 associates who serve over 11 million customers daily through an eCommerce shopping experience and retail food stores under a variety of banner names, serving America through food inspiration and uplift, and creating #ZeroHungerZeroWaste communities. To learn more about us, visit our newsroom and investor relations site.

About Google Cloud

Google Cloud is the new way to the cloud, providing AI, infrastructure, developer, data, security, and collaboration tools built for today and tomorrow. Google Cloud offers a powerful, fully integrated and optimized AI stack with its own planet-scale infrastructure, custom-built chips, generative AI models and development platform, as well as AI-powered applications, to help organizations transform. Customers in more than 200 countries and territories turn to Google Cloud as their trusted technology partner.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kroger-scales-generative-ai-strategy-with-google-cloud-to-drive-digital-growth-and-personalization-302657659.html

SOURCE The Kroger Co.

Posted on

Walmart and Google Turn AI Discovery Into Effortless Shopping Experiences

Walmart and Google Turn AI Discovery Into Effortless Shopping Experiences

Expansive assortment, fast delivery and great prices combine with the power of Gemini to unlock delightful shopping journeys

BENTONVILLE, Ark.–(BUSINESS WIRE)–
Today, Walmart Inc. and Google share plans to launch a new experience that pairs the intelligence of Google’s Gemini with Walmart and Sam’s Club’s unmatched assortment, value and convenience, to make shopping more intuitive, reliable and perfectly aligned with the rhythms of everyday life. The new experience — built by Walmart and accessible directly within Gemini using the Universal Commerce Protocol — addresses several key customer needs:

  • Great items, at great prices: Gemini will automatically include Walmart and Sam’s Club in-store and online products when it’s relevant. For example, when a customer asks for advice on camping equipment for the spring season, it will return items from the retailer’s large inventory of products. And since people talk back-and-forth with Gemini, there are more opportunities to show relevant products and services throughout the conversation.
  • Personalization and familiarity: When customers discover items in Gemini, Walmart helps them move from inspiration to purchase in a seamless, trusted experience — all within the familiar Walmart and Sam’s environments they know and love. When customers link their accounts, Walmart will recommend complementary items based on their past online and in-store purchases, combine their order with other items they’ve put in their Walmart or Sam’s Club carts, and provide all the benefits of their Walmart+ and Sam’s Club memberships.
  • Fast delivery: Customers and members can get in-store and club items delivered right where and when they want it, with hundreds of thousands of locally curated products delivered in under three hours and as fast as 30 minutes.

“The transition from traditional web or app search to agent-led commerce represents the next great evolution in retail. We aren’t just watching the shift, we are driving it,” said John Furner, President and CEO of Walmart U.S. and incoming President and CEO of Walmart Inc. “We want to help customers get what they need and want, when and where they want it. Partnering with Google to bring the Walmart experience directly into Gemini is another step toward creating seamless shopping experiences for customers and members that are more intuitive and personal than ever before.”

“AI can improve every step of the consumer journey, from discovery to delivery. Walmart is an innovator in retail and we are excited to partner with them on a new open standard to make agentic commerce a reality. Customers will soon be able to experience everything they love about Walmart directly in the Gemini app,” said Sundar Pichai, CEO of Google and Alphabet.

The new experience will first launch directly within Gemini in the U.S. and internationally thereafter.

About Walmart

Walmart Inc. (Nasdaq: WMT) is a people-led, tech-powered omnichannel retailer helping people save money and live better — anytime and anywhere — in stores, online, and through their mobile devices. Each week, approximately 270 million customers and members visit more than 10,750 stores and numerous eCommerce websites in 19 countries. With fiscal year 2025 revenue of $681 billion, Walmart employs approximately 2.1 million associates worldwide. Walmart continues to be a leader in sustainability, corporate philanthropy, and employment opportunity. Additional information about Walmart can be found by visiting corporate.walmart.com, on Facebook at facebook.com/walmart, on X (formerly known as Twitter) at twitter.com/walmart, and on LinkedIn at linkedin.com/company/walmart.

Media Contact:

[email protected]

(800) 331-0085

KEYWORDS: United States North America Arkansas

INDUSTRY KEYWORDS: Online Retail Technology Supermarket Discount/Variety Department Stores Electronic Commerce Apps/Applications Retail Software Artificial Intelligence Home Goods

MEDIA:

Logo
Logo
Posted on

The Home Depot and Google Cloud Launch Agentic AI Tools to Help Customers and Associates Bring Projects from ‘How-to’ to ‘Done’

PR Newswire

Expanded partnership introduces AI agents that go beyond advice to take action—giving customers project recommendations and managing complex material orders for pros

NEW YORK, Jan. 11, 2026 /PRNewswire/ — Today at NRF 2026, The Home Depot and Google Cloud announced an expansion of their strategic partnership, further advancing the interconnected retail experience with new agentic AI tools that provide real-time, expert assistance to homeowners and professional customers (pros) like contractors, renovators and remodelers.

Through the deployment of Google Cloud’s AI, The Home Depot is extending its home improvement expertise from the store aisles to customers’ fingertips, including new capabilities in its Magic Apron assistant, AI-powered product list builders for pros, and new tools to improve customer and store support. By deploying Google Cloud’s Gemini models and Gemini Enterprise for Customer Experience (CX), the company is creating a native “AI-first” experience that is personalized, contextual and available wherever the customer is—from the living room to the jobsite to the shelves.

Looking ahead, these capabilities will expand beyond The Home Depot’s own platforms as the company participates in new, agentic shopping experiences across AI Mode in Google Search and the Gemini app in the coming months.

“The Home Depot has always been about providing excellent customer service,” said Jordan Broggi, EVP Customer Experience and President – Online, The Home Depot. “By building on Google Cloud’s AI solutions, we’re putting ‘Orange Apron’ expertise in the pocket of every customer and creating an AI experience that is personalized, contextual, and available wherever the customer is—whether that’s the home, the jobsite, or in the aisles of our stores.”

“We are entering a new chapter of retail where technology doesn’t just suggest products—it solves problems,” said Jose Gomes, vice president, Retail & Consumer Packaged Goods at Google Cloud. “The Home Depot is leading in the agentic commerce era, and using AI to deliver real-world value. By integrating Google Cloud’s AI, The Home Depot is ensuring that customer interactions—whether from a pro on a jobsite or a shopper in an aisle—are powered by the most sophisticated intelligence available today.”

Magic Apron Assistant provides conversational home improvement recommendations and project expertise

The Home Depot significantly expanded its Magic Apron suite of AI tools, transforming them from a simple AI assistant on homedepot.com product pages into conversational, expert digital companions for DIYers and pros across Home Depot digital platforms. Customers can now describe their projects in plain language, and Magic Apron moves beyond simple search results to provide expert conversational advice and personalized recommendations for everything from how to fix a leaky faucet to full kitchen remodels. By integrating the Shopping agent from Gemini Enterprise for CX, The Home Depot is enhancing its Magic Apron platform which will soon have advanced multimodal capabilities, including image upload and visualization that allows the digital concierge to intuitively guide customers through complex home improvement projects.

The Home Depot also built a new store experience in Magic Apron, which integrates the agentic AI experience with real-time local store inventory and product locations—combining its proprietary home improvement knowledge and store wayfinding guidance right in a customer’s pocket. As one of the first localized AI agents of its kind in retail, this expanded functionality provides aisle-level precision, directing customers to the exact bay for any item and offering technical guidance in the aisles. If a customer asks “What grout works best with glass tiles?” Magic Apron will not only provide how-to guides and recommend unsanded or epoxy grout, but it will also show the customer exactly where to find that product in the store and what additional materials the shopper may want to buy. Currently testing at select stores, the company plans to roll out this in-store experience nationwide in the coming months.

Accelerating pro workflows with AI-powered materials lists

For pro customers like renovators, remodelers, and contractors, The Home Depot will offer a new AI-powered materials list feature on its pro digital site. The new feature allows pros to describe a project via voice or text, or even upload a list of products the pro already has. The agent then interprets the project intent to quickly generate a comprehensive, grouped list of materials, even suggesting essential missed items required for the job—significantly accelerating the estimating and planning process for pros. Launched in beta in November 2025 and scaling nationally this month, these lists can help pros generate accurate quotes in a fraction of the time it used to take, so they can focus on bringing in new business more quickly and seamlessly.

Precision at the pavement with AI-powered route intelligence

The Home Depot built a smarter last mile with new route intelligence powered by Gemini and Google Maps Platform. This system predicts and prevents delivery failures by layering customer-specific data—like operating hours and drop-off preferences—with external factors like weather and road quality. Leveraging multimodal AI, the platform interprets Google Maps to spot potential access blockers such as narrow or unpaved streets, gated entries or posts that would make delivery or entry difficult. The new feature unlocks predictive capabilities to anticipate and mitigate delivery risks, ensuring a reliable and consistent customer experience. And by alerting drivers where large trucks may struggle to turn or offload, the system will soon be able to recommend the right equipment and crew size to ensure even the most complex sites receive on-time, complete deliveries.

Bringing a new level of customer service with AI-powered chat, SMS, and voice

The Home Depot is redefining how customers get help by replacing rigid, menu-driven automation with conversational AI that understands intent and resolves issues in real-time. Live today across SMS, chat and phone, the platform allows customers to speak naturally, eliminating the friction and dead ends common in traditional service experiences.

Powered by Gemini Enterprise for CX, the approach is already delivering materially better engagement and resolution outcomes, proving that conversational AI can move beyond deflection of issues to drive real customer impact at enterprise scale. Building on this momentum, The Home Depot is now testing next-generation AI voice agents in select stores, enabling associates to focus on the most complex customer needs.

Gemini Enterprise empowers associates at the Store Support Center

The Home Depot is one of the first companies to equip thousands of associates with Google Cloud’s Gemini Enterprise, a new agentic platform that automates end-to-end business processes. At the company’s Store Support Center, Gemini Enterprise equips teams with specialized agents to automate workflows in seconds, from more easily predicting project bottlenecks, to drafting marketing copy and auditing digital designs. By offloading routine execution, associates can focus on creative problem solving, high-impact strategy, and long-term growth.

About The Home Depot

The Home Depot is the world’s largest home improvement specialty retailer.  At the end of the third quarter of fiscal 2025, the company operated a total of 2,356 retail stores and over 1,200 SRS locations across all 50 states, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, Guam, 10 Canadian provinces and Mexico. The Company employs over 470,000 associates. The Home Depot’s stock is traded on the New York Stock Exchange (NYSE: HD) and is included in the Dow Jones industrial average and Standard & Poor’s 500 index.

About Google        

Google’s mission is to organize the world’s information and make it universally accessible and useful. Through products and platforms like Search, Maps, Gmail, Android, Google Play, Google Cloud, Chrome and YouTube, Google plays a meaningful role in the daily lives of billions of people and has become one of the most widely-known companies in the world. Google is a subsidiary of Alphabet Inc. 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/the-home-depot-and-google-cloud-launch-agentic-ai-tools-to-help-customers-and-associates-bring-projects-from-how-to-to-done-302657836.html

SOURCE Google Cloud

Posted on

Papa Johns and Google Cloud Reimagine the Future of Food Ordering to Better Serve Customers

PR Newswire

Using Google Cloud’s new agentic solution, Gemini Enterprise for Customer Experience, Papa Johns is the first restaurant to bring new omnichannel food ordering capabilities to market

NEW YORK, Jan. 11, 2026 /PRNewswire/ — Today at NRF 2026, Papa Johns announced a major transformation of its digital ordering experience, designed to deliver speed, accuracy, and real-time personalization to its 150 million+ customers worldwide. The QSR leader is the first partner for Google Cloud’s newly expanded AI solution, Food Ordering agent, which is helping the pizza brand deploy a fully unified voice and text AI ordering system to remove friction across customer touchpoints. The Food Ordering agent is a part of Gemini Enterprise for Customer Experience, an agentic solution designed to bring commerce and customer service together on an intelligence backbone.

Moving beyond its initial success in drive-thru automation, Food Ordering agent is a comprehensive omnichannel platform that enables brands to deploy high-quality voice AI agents across mobile apps, websites, telephones, kiosks, and in-car systems. By serving as Google Cloud’s launch customer for these new capabilities, Papa Johns is establishing a new industry benchmark for the “agentic” customer experience.

“Papa Johns is a digitally-driven business and, as such, one of our strategic priorities is investing in our technology to deliver a more seamless experience across our assets and owned channels, better connect with our customers, and support greater efficiency across our operations by leveraging data and AI,” said Kevin Vasconi, chief digital and technology officer, Papa Johns. “Our partnership with Google Cloud embodies our commitment to doing exactly that. We’re using Google Cloud’s Food Ordering agent to reimagine what’s possible for our customers. This isn’t just an app update; it’s a fundamental shift in how our customers interact with our brand digitally, making it faster, smarter, and more seamless than ever before.”

With Food Ordering agent, Papa Johns has developed key features to improve the customer experience, including:

  • Increasing sales through seamless offer navigation: The “Intelligent Deal Wizard” functions as a personal concierge that automatically applies the best value combinations and reduces cart abandonment. This builds immediate brand loyalty and accelerates the checkout process by removing the need for customers to leave the app to hunt for better promo codes.
  • Automating complex orders with precision: The “Advanced Voice & Group Ordering” feature captures revenue from complicated, multi-person orders that traditionally required human intervention. The system handles natural language nuances and real-time modifications with ease, ensuring order accuracy even for the most complex requests.
  • Seamless, no-tap reordering flow: The agent identifies Papa Rewards returning loyalty customers and proactively asks whether they want to reorder their most recent orders. Because many pizza customers often order the same items, enabling a speedy, convenient flow from opening the app to checking out is paramount.

“The retail industry is entering the era of agentic commerce, where AI is an engine for business value,” said Carrie Tharp, vice president of global solutions and industries at Google Cloud. “By being the first to deploy our omnichannel Food Ordering agent, Papa Johns is moving beyond the chatbot era to create a fluid, intelligent experience that meets hungry customers wherever they are, whether they are in their car, on an app, or at a kiosk.”

Papa Johns will be showcasing this technology at the Google Cloud booth 5507 at NRF 2026: Retail’s Big Show in NYC, offering live demos of these new capabilities to attendees, and then to customers nationwide by the end of 2026.

About Papa Johns 

Papa John’s International, Inc. (Nasdaq: PZZA) opened its doors in 1984 with one goal in mind: BETTER INGREDIENTS. BETTER PIZZA.® Papa Johns believes that using high-quality ingredients leads to superior quality pizzas. Its original dough is made of only six ingredients and is fresh, never frozen. Papa Johns tops its pizzas with real cheese made from mozzarella, pizza sauce made with vine-ripened tomatoes that go from vine to can in the same day and meat free of fillers. It was the first national pizza delivery chain to announce the removal of artificial flavors and synthetic colors from its entire food menu. Papa Johns is co-headquartered in Atlanta, Ga. and Louisville, Ky. and is the world’s third-largest pizza delivery company with more than 6,000 restaurants in approximately 50 countries and territories. For more information about the company or to order pizza online, visit www.PapaJohns.com or download the Papa Johns mobile app for iOS or Android.

About Google Cloud 

Google Cloud is the new way to the cloud, providing AI, infrastructure, developer, data, security, and collaboration tools built for today and tomorrow. Google Cloud offers a powerful, fully integrated and optimized AI stack with its own planet-scale infrastructure, custom-built chips, generative AI models and development platform, as well as AI-powered applications, to help organizations transform. Customers in more than 200 countries and territories turn to Google Cloud as their trusted technology partner.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/papa-johns-and-google-cloud-reimagine-the-future-of-food-ordering-to-better-serve-customers-302657329.html

SOURCE Google Cloud

Posted on

RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer

ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) — (Nasdaq: RXST) — RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2025. In addition, the company provided an update on the previously announced Chief Financial Officer transition.

Preliminary Unaudited Fourth Quarter and Full-year 2025 Results

  • Preliminary unaudited fourth quarter 2025 revenue is expected to be approximately $32.6 million, driven by:
    • The sale of 28,611 Light Adjustable Lenses (LAL™/LAL+®); representing a 10% increase in procedure volume compared to the third quarter of 2025; and
    • The sale of 25 Light Delivery Devices (LDD™s), expanding the installed base to 1,134 LDDs as of December 31, 2025.
  • Preliminary unaudited 2025 fiscal year revenue is expected to be approximately $134.5 million, versus November guidance of $125 to $130 million, reflecting:
    • The sale of 109,615 LALs, representing a 12% increase in procedure volume compared to 2024; and
    • The sale of 163 LDDs.
  • Preliminary unaudited cash, cash equivalents and short-term investments as of December 31, 2025, are expected to be $228.1 million.
  • Audited full-year 2025 financial results and full-year 2026 guidance will be announced in conjunction with the company’s fourth quarter earnings release in February.

“Procedure trends during the quarter reflected a continued, measured pace of stabilization and recovery, and we remain encouraged by strong engagement across the field as our unified commercial team deepens customer relationships,” said Ron Kurtz, Chief Executive Officer and President of RxSight. “Despite headwinds in 2025, our team made meaningful progress, enabling us to treat more patients than ever before. With more than 1,100 LDDs installed, approximately 10% share of the premium IOL market, and adoption by over 25% of U.S. cataract surgeons, we exited the year in a strengthened position for sustained, long-term growth.”

New Chief Financial Officer

The company is also pleased to announce that Mark Wilterding has been appointed Chief Financial Officer, effective January 11, 2026. Mark will report to Ron Kurtz and will be responsible for overseeing the company’s finance organization. 

“We are excited to welcome Mark as RxSight’s new Chief Financial Officer”, said Ron Kurtz. “Mark has a proven track record of building strong teams, partnering with key Medtech stakeholders, and driving operational excellence. His leadership and expertise will be particularly valuable as we continue to position RxSight for the future.”

Mr. Wilterding has more than 25 years of financial leadership experience, most recently serving as the Senior Vice President of Global Finance for Edwards Lifesciences, where he joined in 2019. In this role, he oversaw investor relations, financial planning and analysis, treasury, financial operations and strategy, and regional finance teams. Prior to joining Edwards Lifesciences, Mr. Wilterding worked for Medtronic and spent the first 15 years of his career at Citi and Credit Suisse. He received a B.A. in economics from St. Olaf College and an M.B.A. from the Kellogg School of Management at Northwestern University.

“I am thrilled to be joining RxSight, a company offering the only adjustable IOL technology, which is redefining the premium category”, said Mark Wilterding. “RxSight products deliver meaningful value to patients and surgeons, and I am looking forward to supporting their continued advancement as we aim to drive long-term, sustainable growth and shareholder value.”

As previously communicated, Shelley Thunen will support the company in a consulting capacity.

The company’s fourth quarter and full-year 2025 financial and operational results are preliminary and are subject to the completion of the company’s 2025 audit. Audited full-year 2025 and unaudited fourth quarter 2025 financial results are expected to be announced in February 2026.

About RxSight, Inc
.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Forward-Looking Statements

This press release contains forward-looking statements, including: statements concerning: the company’s preliminary unaudited fourth quarter and fiscal 2025 financial and operational results and the anticipated timing of announcing audited full-year 2025 and unaudited fourth quarter 2025 financial results; procedure trends, including the pace of stabilization and recovery in the company’s business; engagement across the field and the ability of the company’s unified commercial team to deepen customer relationships; the growing recognition of the value delivered by the company’s adjustable intraocular lens technology to patients and doctors; expectations regarding continued adoption of the RxSight system, including utilization across the company’s installed base of more than 1,100 Light Delivery Devices, adoption by a meaningful portion of U.S. cataract surgeons, and penetration within the premium IOL market; the company’s ability to treat more patients over time; the company’s plans to continue innovating its adjustable IOL technology and products; the belief that adjustable IOL technology is redefining the premium category and can support sustained, long-term growth; and the potential of the company’s technology, products, and leadership team to drive long-term, sustainable growth and shareholder value. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, including those risks described in the company’s prior press releases and the company’s filings with the Securities and Exchange Commission (SEC), including in Part II, Item 1A (Risk Factors) of the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 5, 2025, and any subsequent filings with the SEC. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

Preliminary Estimates

The foregoing financial and operational results are preliminary estimates. We are in the process of finalizing our financial statements for the year ended December 31, 2025, and our actual results remain subject to completion of those financial statements and their audit by our independent registered public accounting firm. These preliminary estimates are based on information available to management as of the date of this press release and certain related assumptions, which could prove incorrect. Our actual, reported results of operations could differ based on completion of our year end closing procedures, final adjustments and developments that may arise prior to completion of our annual financial statements, and adjustments arising from the audit by our independent registered public accounting firm. You should carefully review our audited, consolidated financial statements for the year ended December 31, 2025 when they become available.

Company contact:

Mark Wilterding
Chief Financial Officer
[email protected]

Investor Relations Contact:

Oliver Moravcevic
VP, Investor Relations
[email protected]